A Randomized, Double-blind, Parallel Group, Phase III Trial to Compare the Efficacy, Safety, and Immunogenicity of TX05 With Herceptin in Subjects With HER2 Positive Early Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Trastuzumab (Primary) ; Cyclophosphamide; Epirubicin; Paclitaxel
- Indications Early breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Tanvex BioPharma
- 27 Sep 2019 Planned End Date changed from 1 Mar 2020 to 1 Dec 2020.
- 27 Sep 2019 Planned primary completion date changed from 1 Feb 2020 to 1 Jun 2020.
- 15 Feb 2018 New trial record